EuroEyes International Eye Clinic Limited (1846) AI Stock Analysis

• Market Cap: HK$895.36M
• Dividend Yield: 4.99%
• Average Volume (3M): 75.43K
• Price to Earnings (P/E): 11.2
• Beta (1Y): 0.22
• Revenue Growth: 0.20%
• EPS Growth: -36.95%
• Country: HK
• Employees: 322
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Care Facilities
• EPS (TTM): 0.12
• Shares Outstanding: 320,706,000
• 10 Day Avg. Volume: 83,300
• 30 Day Avg. Volume: 75,433
• PEG Ratio: -0.52
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ―

EuroEyes International Eye Clinic Limited demonstrates strong financial foundations with robust revenue growth and low leverage. However, challenges are present due to declining profit margins and lack of cash flow transparency. Technical analysis suggests bearish trends and momentum, while valuation metrics indicate the stock is fairly priced with a reasonable dividend yield. These factors combined result in a moderate overall score, with emphasis on improving cash flow and cost management being critical for future performance.

EuroEyes International Eye Clinic Limited Business Overview & Revenue Model

Company Description

EuroEyes International Eye Clinic Limited (1846) is a leading provider of vision correction services in Europe and China. The company specializes in offering a wide range of refractive surgery and eye care solutions, including laser vision correction, refractive lens exchange, and cataract surgeries. With a strong presence in Germany, Denmark, and China, EuroEyes operates state-of-the-art clinics and employs experienced ophthalmologists to deliver high-quality eye care services to its patients.

How the Company Makes Money

EuroEyes International Eye Clinic Limited primarily generates revenue through the provision of surgical eye care services. The company's key revenue streams include fees for laser vision correction procedures, such as LASIK and SMILE, and other advanced refractive surgeries like refractive lens exchange and cataract surgeries. EuroEyes charges patients directly for these procedures, and the revenue is further supported by consultations, pre-operative assessments, and post-operative care. Additionally, the company benefits from its strategic locations in high-demand markets across Europe and China and leverages its reputation for quality and innovation in ophthalmic services to attract a steady flow of patients. Partnerships with medical device manufacturers and suppliers also contribute to the company's ability to provide cutting-edge technology and maintain competitive pricing.

EuroEyes International Eye Clinic Limited Financial Statement Overview

Summary

EuroEyes International Eye Clinic Limited shows a solid financial position with strong revenue growth and low leverage. However, recent declines in profit margins and missing cash flow data may pose challenges. The Balance Sheet remains robust, providing support during potential financial fluctuations. Continued focus on improving cost efficiencies and cash flow management will be crucial to sustain its financial health.

Income Statement

The company shows a consistent revenue growth trajectory, with revenue increasing from HK$427.2M in 2019 to HK$715.7M in 2024, indicating strong demand for its services. The Gross Profit Margin has slightly decreased from 47.8% in 2023 to 40.1% in 2024, suggesting some pressure on cost management. The Net Profit Margin also decreased from 18.4% to 11.5%. Despite these declines, EBIT and EBITDA margins remained reasonably robust, reflecting effective operational management.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of roughly 68.3% in 2024, indicating financial stability. The Debt-to-Equity Ratio is relatively low at 0.29, suggesting low leverage and reduced financial risk. However, a slight decline in Stockholders' Equity from 2023 to 2024 could be a potential concern if it continues.

Cash Flow

The lack of reported Operating Cash Flow and Free Cash Flow in 2024 raises concerns about the company's cash generation capabilities. In prior years, there was positive Free Cash Flow, indicating previously healthy operations. The absence of cash flow data for 2024 could signal potential operational or financial challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	715.68M	714.29M	610.29M	632.93M	473.82M
Gross Profit	286.59M	335.52M	270.84M	312.55M	214.10M
EBITDA	141.89M	292.10M	220.44M	278.80M	173.62M
Net Income	82.28M	131.24M	89.47M	133.56M	65.58M
Balance Sheet
Total Assets	1.60B	1.75B	1.54B	1.37B	1.31B
Cash, Cash Equivalents and Short-Term Investments	680.67M	720.38M	779.57M	861.58M	761.89M
Total Debt	319.29M	384.26M	290.41M	221.48M	239.55M
Total Liabilities	473.72M	588.09M	497.95M	328.55M	324.57M
Stockholders Equity	1.09B	1.13B	1.01B	1.01B	953.29M
Cash Flow
Free Cash Flow	117.41M	102.30M	152.46M	228.71M	40.12M
Operating Cash Flow	197.75M	191.85M	208.76M	273.26M	78.46M
Investing Cash Flow	-83.83M	-180.28M	-131.81M	-59.90M	-38.13M
Financing Cash Flow	-136.82M	-102.76M	-102.22M	-69.18M	-116.37M

EuroEyes International Eye Clinic Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Negative. The current price of 2.8 is below the 20-day moving average (MA) of 2.93, below the 50-day MA of 2.90, and below the 200-day MA of 3.59, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.66 is Neutral, neither overbought nor oversold. The STOCH value of 10.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1846.

EuroEyes International Eye Clinic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2219	74 Outperform	HK$1.97B	9.09	8.35%	8.37%	0.61%	-15.89%
3689	66 Neutral	HK$601.91M	36.14	1.07%	8.89%	-1.20%	-87.51%
6639	63 Neutral	HK$1.17B	38.75	1.27%	―	7.58%	―
1846	61 Neutral	HK$895.36M	11.23	7.39%	4.99%	0.20%	-36.95%
Sector *	60 Neutral	HK$15.27B	5.60	-7.43%	4.22%	11.60%	-21.06%
3309	54 Neutral	HK$2.27B	33.92	-7.51%	1.10%	-0.56%	-323.09%
3869	48 Neutral	HK$594.23M	―	-10.78%	―	-0.95%	-128.35%

EuroEyes International Eye Clinic Limited Corporate Events

EuroEyes Secures Shareholder Approval for Key Resolutions at AGM

EuroEyes International Eye Clinic Limited announced that all resolutions proposed at their Annual General Meeting on June 6, 2025, were approved by shareholders. Key resolutions included the adoption of financial statements, approval of a final dividend, re-election of directors, and authorization for the board to issue and repurchase shares. These approvals indicate strong shareholder support and provide the company with flexibility in its financial and operational strategies.

EuroEyes Reports Q1 2025 Eye Surgery Statistics

EuroEyes International Eye Clinic Limited reported a total of 6,997 eye surgeries in the first quarter of 2025, marking a 3% decrease compared to the same period in 2024 but a 6.7% increase from the previous quarter. The rise in surgeries from the previous quarter was driven by a significant increase in lens exchange surgeries and a robust recovery in Denmark, as well as strong performance in their London flagship clinic and new German clinics.

EuroEyes Announces 2025 Annual General Meeting Agenda

EuroEyes International Eye Clinic Limited has announced its upcoming Annual General Meeting scheduled for June 6, 2025, in Hong Kong. Key agenda items include the adoption of financial statements, approval of a final dividend, re-election of directors, re-appointment of auditors, and granting of mandates to issue and repurchase shares. These decisions are poised to impact the company’s governance and financial strategies, potentially affecting shareholder value and market positioning.

EuroEyes Announces Change of Company Website

EuroEyes International Eye Clinic Limited has announced a change in its company website address from ‘www.euroeyes.hk’ to ‘www.euroeyes.com’, effective from April 23, 2025. This change will ensure that all future announcements and documents submitted to the Hong Kong Stock Exchange will be accessible on the new website, potentially enhancing the company’s online presence and accessibility for stakeholders.